EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fluorescent Multiplex Immunohistochemistry ( mIHC ) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor‐Infiltrating Immune Cells and Predicted the Clinical Outcome

Miaomiao Gou iD, Yunhe Gao, Yong Zhang iD, Niansong Qian, Haixu Hu, Yanju Yu, Jinfeng Li, Zhikuan Wang iD, Zhi Qiao, Guanghai Dai iD, Yi Liu

Cancer Medicine · 2026-07 · 15 (7)

DOI: 10.1002/cam4.72132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.07.2026. Verfasst von Miaomiao Gou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoadjuvant Therapy, Lymphocytes, Tumor-Infiltrating, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) remains heterogeneous. The real‐world efficacy and comparison of triplet regimens against doublet regimens is unclear. Moreover, the immunological mechanisms underlying differential responses to NAC are poorly understood. This study aimed to compare the efficacy of doublet versus triplet NAC in a Chinese LAGC cohort, and characterize the post‐treatment tumor immune microenvironment (TIME) to identify immune correlates of response and survival.

Methods

This retrospective study enrolled patients with locally advanced gastric cancer (GC) who received NAC followed by D2 gastrectomy. The clinical outcomes of patients treated with different NAC regimens were analyzed. The TIME was further characterized using fluorescent multiplex immunohistochemistry (mIHC) to analyze the density and spatial proximity of the immune cells the SOX regimen group.

Results

A total of 141 GC patients with complete survival data were included in the final analysis. The overall efficacy of NAC was consistent with prior reports: 7.8% (11/141) achieved ypT0, 36.2% (51/141) achieved ypN0, and 6.4% (9/141) attained a pathological complete response (pCR). Triplet regimens did not provide a statistically significant survival and response advantage over doublet regimens. mIHC analysis showed longer DFS were consistently associated with higher densities of effector immune cells and lower densities of exhausted/immunosuppressive subsets. Favorable survival was also linked to a closer spatial proximity of CD68 + cells to tumor cells. In treatment response subgroups, responders exhibited distinct spatial patterns, including higher overall CD56 + cell density but fewer CD68 + cells near tumors, alongside a shorter CD56 + ‐to‐tumor distance.

Conclusion

This study confirms the consistent anticancer efficacy of neoadjuvant chemotherapy in LAGC. To better inform individualized post‐NAC treatment strategies, analysis of the TIME using multiplex mIHC on surgical specimens is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsNeoadjuvant TherapyLymphocytes, Tumor-InfiltratingAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesTumor MicroenvironmentMiddle AgedImmunohistochemistryAgedGastrectomyTreatment OutcomePathologic Complete ResponseAdultNeoplasm StagingPrognosisBiomarkers, TumorChemotherapy, Adjuvant

Stichwörter der Autor:innen

gastric cancermultiplex immunohistochemistryneoadjuvant chemotherapytumor immune microenvironmenttumor‐infiltrating immune cells

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Chinese PLA General Hospital, Beijing, China.
  • The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • The Second Medical Center of Chinese PLA General Hospital, Beijing, China.
  • The Eighth Medical Center of Chinese PLA General Hospital, Beijing, China.

ORCID-Profile: Miaomiao Gou, Yong Zhang, Zhikuan Wang, Guanghai Dai

Zitieren

APA

Gou, M., Gao, Y., Zhang, Y., Qian, N., Hu, H., Yu, Y., Li, J., Wang, Z., Qiao, Z., Dai, G., & Liu, Y. (2026). Fluorescent Multiplex Immunohistochemistry ( mIHC ) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor‐Infiltrating Immune Cells and Predicted the Clinical Outcome. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72132

Vancouver

Gou M, Gao Y, Zhang Y, Qian N, Hu H, Yu Y, et al. Fluorescent Multiplex Immunohistochemistry ( mIHC ) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor‐Infiltrating Immune Cells and Predicted the Clinical Outcome. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72132

BibTeX
@article{Gou2026,
  author = {Gou, Miaomiao and Gao, Yunhe and Zhang, Yong and Qian, Niansong and Hu, Haixu and Yu, Yanju and Li, Jinfeng and Wang, Zhikuan and Qiao, Zhi and Dai, Guanghai and Liu, Yi},
  title = {Fluorescent Multiplex Immunohistochemistry ( mIHC ) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor‐Infiltrating Immune Cells and Predicted the Clinical Outcome},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cam4.72132}
}
Kostenlos starten →